Defining resectability: When do you try to take it out?Central Message

Defining resectability: When do you try to take it out?Central Message

Bibliografski detalji
Glavni autori:	Harry Etienne, MD, PhD, Bianca Battilana, MM, Jonathan Spicer, MD, PhD, Raphael S. Werner, MD, MSc, Isabelle Opitz, MD
Format:	Članak
Jezik:	English
Izdano:	Elsevier 2024-06-01
Serija:	JTCVS Open
Teme:	immune checkpoint inhibitors non–small cell lung cancer surgery resectability induction therapy locally advanced non–small cell lung cancer
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2666273624000913

Slični predmeti

Survival after recurrence following surgical resected non-small cell lung cancer: A multicenter, prospective cohort studyCentral MessagePerspective
od: Tomoyoshi Takenaka, MD, PhD, i dr.
Izdano: (2022-06-01)

Lobectomy versus segmentectomy in patients with T1N2 non–small cell lung cancer: An analysis of the National Cancer DatabaseCentral MessagePerspective
od: Yoshiko Iwai, MS, i dr.
Izdano: (2024-10-01)

Lobectomy offers improved survival outcomes relative to segmentectomy for >2 but ≤4 cm non–small cell lung cancer tumorsCentral MessagePerspective
od: Terrance Peng, MD, MPH, i dr.
Izdano: (2022-06-01)

Mediastinal radiotherapy after adjuvant chemotherapy for resected non–small cell lung cancer with N2 lymphadenopathy: A novel meta-analysisCentral MessagePerspective
od: Leanne Harling, PhD, FRCS, i dr.
Izdano: (2021-03-01)

Veterans Affairs Insurance Disparities for Metastatic Lung Cancer in the Hawaiian Islands
od: John Q. Lin, BS, i dr.
Izdano: (2020-03-01)

Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society
od: Yuichi Ozawa, MD, PhD, i dr.
Izdano: (2022-05-01)

Prognostic Impact of Single and Multiple Descriptors in Pathologically Staged T3N0M0 NSCLC
od: Takefumi Komiya, MD, PhD, i dr.
Izdano: (2021-03-01)

Clinical Benefits of Lobe-Specific Lymph Node Dissection in Surgery for NSCLC: A Systematic Review and Meta-Analysis
od: Wongi Woo, MD, i dr.
Izdano: (2023-05-01)

Asia expert consensus on segmentectomy in non–small cell lung cancer: A modified Delphi studyCentral MessagePerspective
od: Lunxu Liu, MD, PhD, i dr.
Izdano: (2023-06-01)

Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060
od: Takehiro Tozuka, MD, i dr.
Izdano: (2024-04-01)

Association of travel distance, surgical volume, and receipt of adjuvant chemotherapy with survival among patients with resectable lung cancerCentral MessagePerspective
od: Charles D. Logan, MD, i dr.
Izdano: (2023-03-01)

Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study
od: Joel W. Neal, MD, PhD, i dr.
Izdano: (2024-10-01)

A case of pulmonary pleomorphic carcinoma associated with cystic airspace
od: Mamiko Iwamura, MD, i dr.
Izdano: (2023-08-01)

Timely Curative Treatment and Overall Mortality Among Veterans With Stage I NSCLC
od: Rolando Sanchez, MD, MS, i dr.
Izdano: (2023-02-01)

Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC
od: Ryo Toyozawa, MD, i dr.
Izdano: (2020-03-01)

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes
od: Anne-Marie Ruppert, MD, PhD, i dr.
Izdano: (2020-09-01)

Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL
od: Shigehiro Yagishita, MD, PhD, i dr.
Izdano: (2024-07-01)

The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma
od: Hiroaki Kanemura, MD, MPH, PhD, i dr.
Izdano: (2024-04-01)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
od: Katsuhiro Yoshimura, MD, i dr.
Izdano: (2017-01-01)

Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer
od: Takehiro Tozuka, MD, i dr.
Izdano: (2024-04-01)

Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy
od: Apar Pataer, MD, PhD, i dr.
Izdano: (2022-11-01)

Highly sensitive noninvasive early lung cancer detection using DNA methylation topology in sputum-derived epithelial cellsCentral MessagePerspective
od: Harmik J. Soukiasian, MD, i dr.
Izdano: (2023-03-01)

Oncological feasibility of segmentectomy for inner-located lung cancerCentral MessagePerspective
od: Kaito Yano, MD, i dr.
Izdano: (2024-04-01)

Conditional survival analysis of patients with resected non–small cell lung cancerCentral MessagePerspective
od: Talib Chaudhry, MD, i dr.
Izdano: (2023-12-01)

Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)
od: Rathi N. Pillai, MD, i dr.
Izdano: (2021-02-01)

Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC—A Brief Report From the CROWN Study
od: Shunsuke Teraoka, MD, i dr.
Izdano: (2024-03-01)

Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC
od: Edward S. Kim, MD, i dr.
Izdano: (2022-01-01)

Brief Report: Impact of Maintenance Pemetrexed Cessation on Clinical Outcomes of Patients With Metastatic Nonsquamous NSCLC
od: Shreya Bhatia, BS, i dr.
Izdano: (2024-11-01)

Genomic profiling and metastatic risk in early-stage non–small cell lung cancerCentral Message
od: Cameron N. Fick, MD, i dr.
Izdano: (2023-12-01)

Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL)
od: Satoru Miura, MD, PhD, i dr.
Izdano: (2023-03-01)

Development and validation of prognostic nomogram for T1-3N0M0 non-small cell lung cancer after curative resection
od: Weijian Mei, i dr.
Izdano: (2023-07-01)

Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLC
od: Daiki Ikarashi, MD, PhD, i dr.
Izdano: (2021-10-01)

What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist
od: Ghanem S, i dr.
Izdano: (2017-07-01)

Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study
od: Hirotsugu Kenmotsu, MD, PhD, i dr.
Izdano: (2024-11-01)

Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study
od: Hiroaki Akamatsu, MD, PhD, i dr.
Izdano: (2021-07-01)

The Role of Radiotherapy in the Treatment of Lung Cancer: A Review of Therapeutic Methods and Effects
od: Dawid Komada, i dr.
Izdano: (2025-02-01)

Impact of Prophylactic Use of PEG-rhG-CSF on First-Line Immunochemotherapy in Advanced NSCLC: A Cohort Study
od: Li Sun, MD, i dr.
Izdano: (2025-02-01)

The Long-Term Outcomes of Induction Chemoradiotherapy Followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer
od: Hidetaka Uramoto, i dr.
Izdano: (2014-10-01)

Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR–Mutated Lung Cancer
od: Naoki Haratake, MD, PhD, i dr.
Izdano: (2020-11-01)

Surgical Complexity of Pulmonary Resections Performed for Oligometastatic NSCLC
od: Mara B. Antonoff, MD, i dr.
Izdano: (2022-03-01)